The FDA has cleared a new breast cancer treatment strategy that does not wait for a scan to show the disease getting worse. Etcamah, AstraZeneca’s newly approved oral breast cancer drug, can be used after a blood test detects a specific resistance mutation, potentially giving doctors an earlier window to change treatment.
The FDA granted accelerated approval to Etcamah, also known as camizestrant, on September 4. The drug is approved in combination with a CDK4/6 inhibitor for certain adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer after an ESR1 mutation emerges during treatment with an aromatase inhibitor and CDK4/6 inhibitor.
According to the FDA, this is the first cancer therapy approved based on detecting a resistance mutation in circulating tumor DNA before imaging shows disease progression. The agency also authorized Guardant360 CDx as a companion diagnostic for identifying eligible patients.
In other words, doctors may be able to catch the cancer changing its game before conventional scans reveal that the current treatment has stopped holding it back.
“It’s a great idea,” University of Pennsylvania breast cancer oncologist Angela DeMichele told Nature Biotechnology. “We switch the person’s therapy away from the drug that they are now theoretically resistant to, to a different drug that they should now be sensitive to.”
Duke University cancer pharmacologist Suzanne Wardell explained the potential benefit even more plainly, saying the approach could improve outcomes “because you’re nipping those mutant cells in the bud, before they can really cause further metastasis and greater disease.”
ER-positive breast cancer represents roughly 70% of breast cancer cases, according to Nature Biotechnology. Hormone-based treatments have been a major weapon against the disease for decades, with CDK4/6 inhibitors later improving treatment for advanced ER-positive, HER2-negative cancers.
The problem is resistance.
ESR1 mutations can develop while patients are receiving endocrine therapy, allowing cancer cells to keep estrogen-receptor signaling active even when treatment is trying to shut it down. The FDA says fewer than 5% of patients have the mutation when HR-positive metastatic breast cancer is initially diagnosed, but nearly 40% have it after progression on an aromatase inhibitor.
Etcamah is designed to attack that resistance differently. The oral drug is an estrogen receptor antagonist, and its approval grew out of the Phase III SERENA-6 trial.
The study screened more than 3,000 patients for emerging ESR1 mutations while they were receiving first-line therapy. Among 315 randomized patients with detectable mutations but no disease progression, researchers compared switching the aromatase inhibitor to camizestrant while continuing a CDK4/6 inhibitor against staying on the existing regimen.
The difference was significant. Median progression-free survival reached 16 months in the Etcamah group compared with 9.2 months in the control group. The FDA reported a hazard ratio of 0.44, translating to a 56% reduction in the risk of disease progression or death during the analysis period.
“If you can tweak the endocrine therapy, you can continue the excellent CDK4/6 inhibitor combination, which we know is very good for patients,” AstraZeneca oncology executive Teresa Klinowska told Nature Biotechnology. “Our hypothesis was to prolong that period for as long as possible.”
There is an important catch. This is an accelerated approval, not the end of the scientific conversation.
The FDA specifically says additional evidence is needed to confirm whether intervening when the mutation first appears in blood, rather than waiting for confirmed disease progression, produces a clinically meaningful long-term benefit. Overall survival data were not mature when the progression-free survival analysis was conducted, and AstraZeneca is required to complete confirmatory work.
The drug also carries safety considerations. Its prescribing information includes a boxed warning concerning the risk of abnormal heart rhythm when Etcamah is used with certain medications that prolong the QTc interval, along with warnings involving bradycardia and potential fetal harm.
And the broader Etcamah story already has another wrinkle. On September 11, AstraZeneca announced that the separate SERENA-4 trial did not achieve its primary objective of a statistically significant progression-free survival improvement when Etcamah plus palbociclib was tested upfront in patients who had not received systemic treatment for advanced disease. That trial studied a different treatment setting from the newly approved ESR1-guided strategy.
Still, researchers are increasingly looking beyond the old model of waiting for visible progression before changing course. Blood-based tumor DNA testing could give doctors another way to track how cancers evolve under treatment and identify resistance while it is developing.
As DeMichele put it, estrogen receptors remain a crucial target because researchers have “not found another node in the progression of breast cancer that is so critical.”
For patients dealing with metastatic disease, that makes the Etcamah approval bigger than simply adding another pill to the pharmacy shelf. The real shift is timing: finding evidence that a treatment is losing its grip and making a move before the cancer gets the chance to make that failure obvious.
